InsiderTrades.com logo
Blackrock’s Sending THIS Crypto Higher on Purpose
From Crypto 101 Media   |   Ad
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
YES, I WANT THE #1 CRYPTO NOW
Pablo G. Legorreta net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Pablo Legorreta Biography and Net Worth

Director of Epizyme
Pablo Legorreta is the Founder and Chief Executive of Royalty Pharma. Mr. Legorreta has over 20 years of experience investing in pharmaceutical royalties, and building and managing a rapidly growing life sciences investment company that is today one of the largest dedicated life sciences investors in the world. Prior to founding Royalty Pharma in 1996, Mr. Legorreta was an investment banker at Lazard Frères in Paris and New York. Mr. Legorreta is also a Co-Founder of Pharmakon Advisors, a leading provider of debt capital to the life sciences industry. Mr. Legorreta serves on the Board of Governors of the New York Academy of Sciences, as well as the Boards of Trustees of Rockefeller University, Brown University, the Hospital for Special Surgery, Pasteur Foundation (the U.S. affiliate of the French Institute Pasteur), Open Medical Institute and Park Avenue Armory. Mr. Legorreta is the Founder and Chairman of Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America by providing doctors and healthcare providers with continued education opportunities. Mr. Legorreta has a degree in industrial engineering from Universidad Iberoamericana in Mexico City.

What is Pablo G. Legorreta's net worth?

The estimated net worth of Pablo G. Legorreta is at least $33.25 million as of June 13th, 2024. Mr. Legorreta owns 22,617,909 shares of Epizyme stock worth more than $33,248,326 as of November 6th. This net worth evaluation does not reflect any other investments that Mr. Legorreta may own. Learn More about Pablo G. Legorreta's net worth.

How do I contact Pablo G. Legorreta?

The corporate mailing address for Mr. Legorreta and other Epizyme executives is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Epizyme can also be reached via phone at (617) 229-5872 and via email at [email protected]. Learn More on Pablo G. Legorreta's contact information.

Has Pablo G. Legorreta been buying or selling shares of Epizyme?

Pablo G. Legorreta has not been actively trading shares of Epizyme within the last three months. Most recently, on Monday, January 31st, Pablo G. Legorreta bought 22,666,667 shares of Epizyme stock. The stock was acquired at an average cost of $1.50 per share, with a total value of $34,000,000.50. Learn More on Pablo G. Legorreta's trading history.

Who are Epizyme's active insiders?

Epizyme's insider roster includes Shefali Agarwal (Insider), Robert Bazemore Jr. (CEO), Joseph Beaulieu (Insider), Jeffery Kutok (Insider), Pablo Legorreta (Director), and David Mott (Director). Learn More on Epizyme's active insiders.

Pablo G. Legorreta Insider Trading History at Epizyme

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/31/2022Buy22,666,667$1.50$34,000,000.50View SEC Filing Icon  
See Full Table

Pablo G. Legorreta Buying and Selling Activity at Epizyme

This chart shows Pablo G Legorreta's buying and selling at Epizyme by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Epizyme Company Overview

Epizyme logo
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.47
Low: $1.47
High: $1.47

50 Day Range

MA: $1.47
Low: $1.47
High: $1.52

2 Week Range

Now: $1.47
Low: $0.41
High: $5.80

Volume

7,960 shs

Average Volume

3,225,203 shs

Market Capitalization

$247.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Blackrock’s Sending THIS Crypto Higher on Purpose
From Crypto 101 Media   |   Ad
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
YES, I WANT THE #1 CRYPTO NOW